Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T49689
(Former ID: TTDI01731)
|
|||||
Target Name |
Immunoglobulin G1k (IgG1k)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Sickle-cell disorder [ICD-11: 3A51] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | NKTT-120 | Drug Info | Phase 1 | Sickle-cell disorder | [2], [3] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42. | |||||
REF 2 | ClinicalTrials.gov (NCT01783691) Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD). U.S. National Institutes of Health. | |||||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.